Related Experiment Video
Updated: Aug 16, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces
Birgit Jaschke1, Cornelia Michaelis, Stefan Milz
1Deutsches Herzzentrum and 1. Medizinische Klinik, Technische Universität, Munich, Germany.
Objective:
Therapeutic strategies to provide local inhibition of mitogen mediated proliferation and migration of human coronary artery smooth muscle cells (CASMC) by means of drug-eluting stents have been shown to enable effective limitation of neointimal hyperplasia. However, currently available drug-eluting stents utilize compounds that may also adversely affect endothelial regrowth, thus possibly precipitating subsequent cardiac events. Accordingly, identification of compounds that differentially inhibit smooth muscle and endothelial cell migration and proliferation could be of substantial clinical usefulness.
Methods And Results:
In addition to lipid lowering, statins are known to display auxiliary pleiotropic activities. The purpose of this study was to evaluate the effect of local administration of cerivastatin on proliferation, migration and cytotoxicity of CASMC as well as coronary artery endothelial cells (CAEC) and to evaluate the effect of cerivastatin-coated stents on the inhibition of neointima formation as well as endothelial regrowth within the stented vessel. Cerivastatin displayed a differential effect on CASMC as compared to CAEC with regard to proliferation and migration; both were more profoundly inhibited in CASMC. Appreciable cytotoxicity and pro-apoptotic effects were low in both cell lines at therapeutic concentrations. Cerivastatin-elution led to significant inhibition of neointima formation in the rat carotid stent model, endothelial coverage of in-stent vascular tissue was similar with control and cerivastatin-eluting stents.
Conclusions:
As proof of principle, our study provides evidence that local application of a HMG-CoA reductase inhibitor on a drug-eluting stent platform can efficiently limit neointima formation. Consequently, these compounds warrant further clinical evaluation to confirm this finding. Our data further suggest that the anti-restenotic effect of local statin administration might be associated with a more protective interaction with the endothelium than that observed with compounds currently employed on drug-eluting stents.
Insights
Local statin delivery via drug-eluting stents effectively limits neointimal hyperplasia without harming endothelial regrowth. This offers a promising alternative to current treatments for preventing cardiac events after stenting.
Area of Science:
- Cardiovascular Research
- Pharmacology
- Biomedical Engineering
Background:
- Drug-eluting stents (DES) limit neointimal hyperplasia but can impair endothelial regrowth, increasing cardiac event risk.
- Identifying agents that selectively inhibit smooth muscle cell proliferation and migration is crucial for improved DES therapy.
Purpose of the Study:
- To evaluate cerivastatin's local effects on coronary artery smooth muscle cells (CASMC) and endothelial cells (CAEC).
- To assess cerivastatin-eluting stents' efficacy in inhibiting neointima formation and promoting endothelial regrowth.
Main Methods:
- In vitro assessment of cerivastatin's impact on CASMC and CAEC proliferation, migration, and cytotoxicity.
- In vivo evaluation of cerivastatin-eluting stents in a rat carotid artery model.
Main Results:
- Cerivastatin differentially inhibited CASMC proliferation and migration more than CAEC.
- Therapeutic concentrations showed minimal cytotoxicity in both cell types.
- Cerivastatin-eluting stents significantly reduced neointima formation.
- Endothelial coverage was comparable between cerivastatin-eluting and control stents.
Conclusions:
- Local cerivastatin delivery via DES platforms can effectively limit neointima formation.
- Statins warrant further clinical investigation for their anti-restenotic potential.
- Local statin administration may offer a more endothelium-friendly approach compared to current DES compounds.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis I: Introduction
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Peripheral Artery Disease III: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
